March 28, 2022
We are currently recruiting PhD students (2 openings) and postdoctoral researchers (2 openings). Welcome to apply! [PhD Openings][Postdoc Openings]...... Read More
Yang Engineering Immunity Lab
"Hope lies in dreams, in imagination, and in Our research centers on deciphering the cellular and molecular mechanisms controlling antitumor immunity, and exploiting knowledge to device the next-generation cancer immunotherapies.
Two active research projects are:
Li Y-R*, Zhou Y*, Kim Y, Zhu Y, Ma F, Yu J, Wang Y-C, Chen X, Li Z, Zeng S, Wang X, Lee D, Ku J, Tsao T, Hardoy C, Huang J, Cheng D, Montel-Hagen A, Seet CS, Crooks GM, Larson SM, Sasine JP, Wang X, Pellegrini M, Ribas A, Kohn DB, Witte O, Wang P, and Yang L. (*Co-first authors). Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. Cell Rep Med. 2021, 2(11):100449. [Cell Reports Medicine PDF][UCLA News PDF][BSCRC News PDF][JCCC News PDF][Life Sciences News PDF][Science Daily PDF][CIRM Blog PDF]
Wang Y-C, Wang X, Yu J, Ma F, Li Z, Zhou Y, Zeng S, Ma X, Li Y-R, Neal A, Huang J, To A, Clarke N, Memarzadeh S, Pellegrini M, and Yang L. Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy. Nat Commun. 2021, 12:3530. [Nature Communications PDF][UCLA News PDF][CBS News PDF][NBC News PDF][Fierce Biotech News PDF][Drug Target Review News PDF]
Wang X, Li B, Kim Y, Wang Y, Li Z, Yu J, Zeng S, Ma X, Choi I, Di Biase S, Smith DJ, Zhou Y, Li Y, Ma F, Huang J, Clarke N, To A, Gong L, Pham A, Moon H, Pellegrini M, and Yang L. Targeting monoamine oxidase A for T cell-based cancer immunotherapy. Sci Immunol. 2021, 6:eabh2383. [Science Immunology PDF][Science Magazine News PDF][UCLA News PDF][CBS News PDF][NBC News PDF][Fierce Biotech News PDF][Drug Target Review News PDF]
We are currently recruiting PhD students (2 openings) and postdoctoral researchers (2 openings). Welcome to apply! [PhD Openings][Postdoc Openings]...... Read More
May 7, 2022- Our review article is published on Cells, reporting the engineering of iPSCs for cancer immunotherapy. Congratulations to...... Read More
March 24, 2022- Dr. Lili Yang is featured in “Her Story” at the UCLA Women’s History Month. Congratulations! [UCLA on...... Read More
May 11, 2021- Our off-the-shelf cell therapy technology is licensed by a Biotech startup, Appia Bio, for commercial development. The...... Read More
Dr. Lili Yang receives a $5.9 million CIRM Partnering Opportunity for Translational Research Projects Award to translate a new stem...... Read More